NEO on Nasdaq

NeoGenomics

Logo: NeoGenomics, Public domain, via Wikimedia Commons4

Cancer-focused genetic testing and lab services company

NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 18, 2026.

Overview

2002Founded1

Compare with UL Solutions Inc., Hypha Labs, Inc. or 20/20 Biolabs, Inc., or pick any stock.

  • TickerNEO on Nasdaq1
  • Industrybiotechnology1
  • HeadquartersFort Myers1
  • Websiteneogenomics.com
  • Legal formcorporation1
  • Incorporated inNV5
  • Business address9490 Neogenomics Way, Fort Myers, Fl 339125
  • Filer categoryLarge accelerated filer5

See how the biggest companies compare on our leaderboards

NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

43.2%Gross margin7
-15.9%Operating margin7
-14.9%Net margin7
10.1%Revenue growth, 20257
-12.9%Return on equity7
0.41×Debt to equity7
-$21.8MFree cash flow7

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Client Direct Billing brought in 71% of the revenue NeoGenomics broke down this way in fiscal 2025.

  1. Client Direct Billing$518.8M771%up 9% from 2024
  2. Commercial Insurance$117.5M716%up 18% from 2024
  3. Medicare And Other Governmental$90.9M712%up 7% from 2024
  4. Self Pay Services$114.0K70%down 83% from 2024
Products and services by year
Products and services202320242025
Client Direct Billing$428.9M$475.4M$518.8M
Commercial Insurance$88.0M$99.8M$117.5M
Medicare And Other Governmental$74.4M$84.6M$90.9M
Self Pay Services$350.0K$681.0K$114.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue57¢$413.0M
  • Research and development5¢$37.1M
  • Other costs38¢$275.0M
  • Income tax0¢$2.2M

Out of $727.3M in revenue.7 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Capital spending100¢$27.0M

Out of $5.2M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.7

Financial statements

Revenue8910117$727.3M in 2025+78% since 2019
0$200.0M$400.0M$600.0M$800.0M2019: $408.8M$408.8M20192020: $444.4M$444.4M2020+9%2021: $484.3M$484.3M2021+9%2022: $509.7M$509.7M2022+5%2023: $591.6M$591.6M2023+16%2024: $660.6M$660.6M2024+12%2025: $727.3M$727.3M2025+10%
Gross profit8910117$314.3M in 2025+60% since 2019
0$100.0M$200.0M$300.0M$400.0M2019: $196.8M$196.8M20192020: $185.9M$185.9M2020−6%2021: $187.1M$187.1M2021+1%2022: $187.9M$187.9M2022+0%2023: $244.6M$244.6M2023+30%2024: $290.1M$290.1M2024+19%2025: $314.3M$314.3M2025+8%
Operating income8910117-$115.9M in 2025
-$200.0M-$150.0M-$100.0M-$50.0M0$50.0M2019: $13.0M$13.0M20192020: -$14.0M-$14.0M20202021: -$118.8M-$118.8M2021+749%2022: -$157.6M-$157.6M2022+33%2023: -$107.7M-$107.7M2023−32%2024: -$92.1M-$92.1M2024−15%2025: -$115.9M-$115.9M2025+26%
Net income8910117-$108.0M in 2025
-$150.0M-$100.0M-$50.0M0$50.0M2019: $8.0M$8.0M20192020: $4.2M$4.2M2020−48%2021: -$8.3M-$8.3M20212022: -$144.2M-$144.2M2022+1628%2023: -$88.0M-$88.0M2023−39%2024: -$78.7M-$78.7M2024−11%2025: -$108.0M-$108.0M2025+37%

Every line of the income statement as filed: the last 3 fiscal years, latest first.7

Period ending2025-12-312024-12-312023-12-31
NET REVENUE$727.3M$660.6M$591.6M
COST OF REVENUE$413.0M$370.5M$347.0M
GROSS MARGIN$314.3M$290.1M$244.6M
General and administrative$273.3M$259.7M$243.1M
Research and development$37.1M$31.2M$27.3M
Sales and marketing$92.0M$84.7M$70.8M
Restructuring charges$0$6.7M$11.1M
Impairment charges (Note 3 and Note 7)$27.8M$0$0
Total operating expenses$430.2M$382.2M$352.3M
LOSS FROM OPERATIONS-$115.9M-$92.1M-$107.7M
Interest income-$9.1M-$18.4M-$16.9M
Interest expense$3.8M$6.6M$6.9M
Other (income) expense, net-$296.0K$379.0K-$644.0K
Loss before taxes-$110.3M-$80.7M-$97.1M
Income tax benefit-$2.2M-$1.9M-$9.1M
NET LOSS-$108.0M-$78.7M-$88.0M
Basic (in dollars per share)-$1-$1-$1
Diluted (in dollars per share)-$1-$1-$1
Basic (in shares)128.1M shares126.7M shares125.5M shares
Diluted (in shares)128.1M shares126.7M shares125.5M shares

Compare NeoGenomics with another company

The story

NeoGenomics first received state and national-level laboratory certifications in 2002. Three years later in 2005, the company developed a technical-only service model using FISH.

In 2013, the company launched its sequencing platform and was listed on the Nasdaq Stock Market as NEO. In 2014, NeoGenomics launched molecular tests including BTK and CALR mutation analysis.

In 2015, NeoGenomics acquired Clarient, Inc. and its subsidiary company, Clarient Diagnostic Services, Inc., a national cancer diagnostics laboratory with capabilities in immunohistochemistry for solid tumor cancers from GE Healthcare. Clarient is headquartered in Aliso Viejo, California; with an ancillary laboratory in Houston, Texas.

In November 2017, NeoGenomics established their first headquarters outside the United States in Rolle, Switzerland.

In September 2024, the District Court for the Middle District of North Carolina entered a permanent injunction against NeoGenomics’ accused RaDaR assay, which was preliminarily enjoined in December 2023.

From Wikipedia’s article on NeoGenomics, shared under CC BY-SA 4.0.6

Leadership

Who has led NeoGenomics, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Oort Douglas M. Van2011–2021
  2. Mark Mallon2021–2022
  3. Anthony P. Zook2025–now

Chair

  1. Oort Douglas M. Van2011–2021

President

  1. Steven G. Brodie2016–2017
  2. Robert J. Shovlin2017–2021
  3. George Cardoza2018–2022
  4. William Bonello2020–2021
  5. Clive Morris2021
  6. Gina M. Wallar2021–2022
  7. David Sholehvar2022
  8. Vishal Sikri2022–2024
  9. Shashikant Kulkarni2022
  10. Warren Stone2022–2024
  11. Melody Harris2022–2024

Chief financial officer

  1. George Cardoza2011–2018
  2. Sharon Virag2018–2019
  3. Kathryn B. McKenzie2020–2021
  4. William Bonello2022

Chief operating officer

  1. Robert J. Shovlin2014–2015
  2. George Cardoza2021–2022
  3. Warren Stone2025–now
20052010201520202025
Board members and other officers (43)

Former names

  • AMERICAN COMMUNICATIONS ENTERPRISES INCApr 8, 1999 to Feb 5, 20025

Timeline

  1. Apr 3, 2025New chief executive Anthony P. Zook becomes CEO15
  2. Apr 21, 2021New chief executive Mark Mallon becomes CEO16
  3. May 2, 2011New chief executive Oort Douglas M. Van becomes CEO17
  4. 2002Founded Founded1

Filings

381 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 67 major events, 224 insider forms, 34 large holders, 36 other. The latest 20:

  1. Oct 5, 20264 EDGAR
  2. Oct 5, 20268-K EDGAR
  3. Sep 3, 20264 EDGAR
  4. Aug 25, 20264 EDGAR
  5. Aug 25, 2026S-8 EDGAR
  6. Aug 14, 2026SCHEDULE 13G/A EDGAR
  7. Aug 11, 20268-K EDGAR
  8. Aug 6, 20264 EDGAR
  9. Aug 4, 2026144 EDGAR
  10. Jul 30, 2026SCHEDULE 13G/A EDGAR
  11. Jul 30, 2026144 EDGAR
  12. Jul 30, 2026SCHEDULE 13G EDGAR
  13. Jul 28, 202610-Q EDGAR
  14. Jul 28, 20268-K EDGAR
  15. Jul 22, 20268-K/A EDGAR
  16. Jul 20, 20268-K EDGAR
  17. Jun 25, 20264 EDGAR
  18. Jun 25, 20263 EDGAR
  19. Jun 25, 20268-K EDGAR
  20. Jun 22, 20268-K EDGAR

The 381 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 34 such filings since October 2021, the latest 10:

  1. Aug 14, 2026SCHEDULE 13G/A
  2. Jul 30, 2026SCHEDULE 13G/A
  3. Jul 30, 2026SCHEDULE 13G
  4. May 15, 2026SCHEDULE 13G/A
  5. May 13, 2026SCHEDULE 13G/A
  6. May 7, 2026SCHEDULE 13G/A
  7. Apr 30, 2026SCHEDULE 13G
  8. Apr 29, 2026SCHEDULE 13G
  9. Mar 27, 2026SCHEDULE 13G/A
  10. Dec 9, 2025SCHEDULE 13G

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.20,868,362$304.5M0.0%+910,860
First Light Asset Management, LLC12,279,523$179.2M10.9%+2,549,545
First Trust Advisors LP10,113,261$147.6M0.1%+3,950,890
Greenhouse Funds LLLP8,574,210$125.1M6.6%−525,893
Vanguard Portfolio Management LLC8,061,362$117.6M0.0%+439,175
Vanguard Capital Management LLC5,763,017$84.1M0.0%+107,194
State Street Corp5,363,784$78.3M0.0%+243,946
Nomura Asset Management International Inc.5,037,787$73.5M0.1%+1,585,200
Braidwell LP4,918,202$71.8M2.8%−699,200
Schroder Investment Management Group4,342,883$61.9M0.0%+774,305
Geode Capital Management, LLC3,428,123$50.0M0.0%+197,051
Millennium Management LLC3,079,542$44.9M0.0%+856,785
Loomis Sayles & Co L P2,537,717$37.0M0.0%+592,329
Driehaus Capital Management LLC2,508,845$36.6M0.2%+787,095
Bank Of America Corp /de/2,436,329$35.5M0.0%−617,869
Dimensional Fund Advisors LP2,399,411$35.0M0.0%−274,924
Arrowstreet Capital, Limited Partnership2,391,784$34.9M0.0%New
American Capital Management Inc2,237,707$32.6M1.5%−13,171
D. E. Shaw & Co., Inc.2,194,758$32.0M0.0%−1,969,425
Samlyn Capital, LLC2,131,337$31.1M0.5%−426,012
Aberdeen Group plc1,931,525$28.2M0.0%−95,368
Morgan Stanley1,898,128$27.7M0.0%−264,655
Goldman Sachs Group Inc1,566,760$22.9M0.0%+563,137
Northern Trust Corp1,539,181$22.5M0.0%−41,646
Glenmede Trust Co Na1,517,586$22.1M0.1%+220,403

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

6 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Aug 7, 2026Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000+4.3%Report
May 7, 2025Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000+78.1%Report
Mar 30, 2022Dwight EvansDemocratic, HouseSale$1,001 - $15,000+35.1%Report
Dec 30, 2021Deborah K. RossDemocratic, HouseBuy$15,001 - $50,000−111.6%Report
Nov 9, 2021Bob Gibbs, HouseSale$1,001 - $15,000+125.4%Report
Mar 2, 2020Dwight EvansDemocratic, HouseBuy$1,001 - $15,000−191.2%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76